Trade GRI anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
GRI Bio, Inc. (GRI) is trading at US$2.00, down 30.52% today as of Sep 8, 12:08 EDT. The company has a market capitalisation of US$3.61M. Over the past 52 weeks, GRI has traded between US$1.36 and US$80.36. On Syfe you can trade GRI with $0 commission and add it to your watchlist.
| Previous close | US$2.88 |
|---|---|
| Market cap | US$3.61M |
| 52-week range | US$1.36 – US$80.36 |
| Volume | 7.46M |
| Exchange | US |
Add to Watchlist
Set Price Alert
GRI Bio, Inc.
GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.
Year: 2023
GRI Bio Receives FDA Orphan Drug Designation for GRI-0621 to Treat Idiopathic Pulmonary Fibrosis
Jun 18, 12:48 PM · MT Newswires
GRI Bio, Inc. (GRI) stock is trading at US$2.00, -30.52% from the previous close of US$2.88.
The market cap for GRI Bio, Inc. (GRI) stock is approximately US$3.61M.
The 52-week high for GRI Bio, Inc. (GRI) stock is US$80.36.
The 52-week low for GRI Bio, Inc. (GRI) stock is US$1.36.
GRI Bio, Inc. (GRI) does not currently pay a dividend.
Stay on top of GRI
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
